MDM2 Inhibitor Crystallization for High-Purity Scalable Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cancers, particularly p53 wildtype (p53WT) tumors, are inadequate due to the inactivation of the p53 pathway, which is often targeted by MDM2, leading to unregulated cell growth and tumor progression.
Innovation Solution
Development of a compound that inhibits the interaction between p53 and MDM2, activating p53 downstream effector genes, and providing crystalline forms of the compound for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for p53WT tumors, then treatment is provided, but the treatments are inadequate due to MDM2-mediated p53 pathway inactivation
Solution Approach 1:
The patent uses MDM2 as an intermediary target to indirectly activate p53 function. By developing small molecule inhibitors that bind to MDM2 and block its E3 ubiquitin ligase activity, the invention prevents MDM2 from degrading p53, thereby restoring p53-mediated tumor suppression in p53WT tumors without directly targeting p53 itself.
2Reliability
If MDM2 is inhibited to restore p53 function, then p53 downstream effector genes are activated, but the compound must achieve sufficient potency and selectivity
Solution Approach 1:
The patent employs structure-activity relationship (SAR) analysis to optimize compound parameters including potency (IC50 values), selectivity ratios, and pharmacokinetic properties. Multiple analogs with varying substituents (e.g., halogen atoms at different positions, different side chains) were synthesized and evaluated to identify compounds with optimal binding affinity to MDM2 and selective inhibition of the MDM2-p53 interaction.
3Reliability
If small molecule MDM2 inhibitors are developed, then tumor growth is reduced in vitro and in vivo, but the synthesis and purification processes must be optimized
Solution Approach 1:
The patent divides the complex synthesis of MDM2 inhibitors into discrete, modular steps including: (1) synthesis of core piperidine structures with controlled stereochemistry, (2) introduction of aromatic substituents through cross-coupling reactions, (3) installation of side chains containing basic amino groups, and (4) purification via crystallization. Each step is optimized independently to facilitate scalable manufacturing.
Solution Approach 2:
The patent utilizes crystallization as a key purification step to isolate MDM2 inhibitors from reaction mixtures. By controlling solvent selection, temperature, and addition rates, the compounds are induced to crystallize in high purity form, facilitating easy separation and purification without requiring complex chromatographic procedures.
4Reliability
If MDM2-p53 interaction is neutralized, then p53 degradation is blocked and transcriptional activation is restored, but the compound must maintain stability and pharmacokinetic properties
Solution Approach 1:
The patent develops MDM2 inhibitors with composite molecular structures combining a basic amino-containing side chain (for ionic interaction with acidic residues in MDM2's p53-binding groove) and an aromatic core structure (for hydrophobic and pi-stacking interactions). This composite structure provides both high binding affinity and resistance to metabolic degradation, enhancing compound stability and pharmacokinetic properties.
Data Source
AI summary
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.